M&A Deal Summary

Sanofi Acquires Translate Bio

On August 3, 2021, Sanofi acquired life science company Translate Bio for 3.2B USD

Acquisition Highlights
  • This is Sanofi’s 16th transaction in the Life Science sector.
  • This is Sanofi’s 5th largest (disclosed) transaction.
  • This is Sanofi’s 14th transaction in the United States.
  • This is Sanofi’s 4th transaction in Massachusetts.

M&A Deal Summary
Date 2021-08-03
Target Translate Bio
Sector Life Science
Buyer(s) Sanofi
Deal Type Add-on Acquisition
Deal Value 3.2B USD
Advisor(s) Centerview Partners
Evercore Group
MTS Health Partners LP (Financial)
Paul, Weiss, Rifkind, Wharton & Garrison (Legal)

Target

Translate Bio

Lexington, Massachusetts, United States
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio was founded in 2011 and is based in Lexington, Massachusetts.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sanofi

Paris, France
Category Company
Founded 1994
Sector Life Science
Employees86,088
Revenue 46.4B EUR (2023)
DESCRIPTION

Sanofi is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi was founded in 1994 and is based in Paris, France.

DEAL STATS #
Overall 25 of 27
Sector (Life Science) 16 of 18
Type (Add-on Acquisition) 19 of 21
State (Massachusetts) 4 of 4
Country (United States) 14 of 16
Year (2021) 3 of 4
Size (of disclosed) 5 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-26 Kiadis Pharma

Amsterdam, Netherlands

Kiadis Pharma is a clinical stage biopharmaceutical company pioneering a proprietary cell-based, personalized therapy for patients with blood cancers and related disorders, an area of significant unmet medical need.Kiadis Pharma’s unique and powerful platform technology has led to an initial experimental product, ATIR™, which has already been clinically tested on sixty patients. Kiadis Pharma is based in Amsterdam, Netherlands.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-21 Amunix

South San Francisco, California, United States

Amunix is an immuno-oncology company focused on designing and developing masked T cell engagers and cytokines to bring the promise of these potent immune-activating biotherapeutics to patients with cancers. Amunix is headquartered in South San Francisco, California.

Buy -
Mergr

Product

Company

Legal